Table 2

Demographic data and baseline characteristics of the patients

Characteristics

Placebo (n = 23)

100 mg/day 5-Loxin® (n = 24)

250 mg/day 5-Loxin® (n = 23)


Sex (male/female; n)

5/18

7/17

8/15

Age (years)

52.43 ± 9.65

52.37 ± 8.37

53.22 ± 8.73

Body weight (kg)

61.48 ± 10.69

61.08 ± 10.67

54.84 ± 10.19

Body mass index (kg/m2)

26.05 ± 4.29

25.91 ± 4.94

22.64 ± 4.07

Visual analog score (mm)

56.88 ± 12.04

57.05 ± 8.71

55.62 ± 9.26

Lequesne's Functional Index

12.76 ± 2.6

12.1 ± 2.76

12.04 ± 3.03

WOMAC score

Pain subscale

38.04 ± 9.7

48.08 ± 14.05

37.17 ± 13.8

Stiffness subscale

33.15 ± 13.3

31.8 ± 17.6

27.7 ± 16.8

Function subscale

41.3 ± 9.6

41.5 ± 11.1

38.6 ± 11.1


Values are expressed as mean ± standard deviation. WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

Sengupta et al. Arthritis Research & Therapy 2008 10:R85   doi:10.1186/ar2461

Open Data